SHP2 inhibitor · small molecule
vociprotafib
1 active trials across 3 of our biomarkers, targeting SHP2. Not approved for any biomarker on marked.bio yet.
Also known as RMC-4630.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| KRAS G12C | 1 | 6 | Phase 1 |
| EGFR exon 19 deletion / L858R | 0 | 1 | – |
| KRAS G12D | 0 | 3 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of vociprotafib.
- Amgen 1
Trials
1 of 6 trials shown
-
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
sotorasib FDA EUtrametinibvociprotafibafatinibpembrolizumabpanitumumab FDAcarboplatinpemetrexeddocetaxelpaclitaxelatezolizumabpalbociclib
Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…
KRAS G12CAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
-
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
vociprotafibsotorasib FDA EU
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
KRAS G12CNon-Small Cell Lung Cancer
-
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
vociprotafibpembrolizumabadagrasib FDA EU
Participants must have following molecular aberration (Part 3A and 3B): - KRAS G12C mutation.
KRAS G12CKRAS G12DMetastatic Neoplasm
-
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
vociprotafibcobimetinibosimertinib FDA EU
For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not amenable to curative surgery or radiotherapy
EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DSolid Tumor
-
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
vociprotafibLY3214996
Part A: Histological or cytological proof of advanced KRASm NSCLC, CRC or PDAC
KRAS G12CKRAS G12DPancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, KRAS Mutation-Related Tumors
-
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
…sion Component must have one of the following genotypic aberrations: KRAS amplifications, KRASG12C (NSCLC), BRAF Class 3, or NF1 LOF (NSCLC and gynecological cancers) mutations
KRAS G12CSolid Tumors
No trials match these filters.